Brain Tumor Committee


The NRG Brain Tumor Committee's charge is to pursue clinical research to better the survival and survivorship of patients with primary and secondary tumors of the central nervous system. Their focus areas are metastatic disease to the central nervous system, primary glial tumors, and additional brain neoplasms such as meningioma, primary central nervous system lymphoma, and others.  Our primary research priorities are to identify strategies to improve survival, maintain quality of life and cognitive function, investigate and provide optional palliative strategies, test and evaluate novel targeted and therapeutic strategies, and pursue combinatorial therapies. Overarching goals of the committee include: identifying the best approaches to manage brain metastases; identifying approaches to lengthen survival for patients with malignant glioma; identifying and ameliorating factors responsible for toxicities, cognitive decline, and reduction in quality of life for patient with longer survival; and, identifying the best approaches to maximize local control and enhance cure for locally recurrent tumors. This committee meets monthly via teleconference and in-person at the NRG Semiannual Meetings.

Brain Tumor Committee Leadership


Minesh Mehta, MD

Vice Chair

Michael Vogelbaum, MD, PhD

Vice Chair

Mark Gilbert, MD

Vice Chair

Arnab Chakravarti, MD

Working Groups

IDHwt Glioma

IDHmut Glioma


Translational Science Brain Tumor Working Group


Arnab Chakravarti, MD

Committee Members

Core Committee Members

  • Manmeet Ahluwalia
  • Ken Aldape
  • Drexell Hunter Boggs
  • Paul D. Brown
  • Stuart Burri
  • Arnab Chakravarti 
  • Michael Chan
  • Prakash Chinnaiyan
  • Mark Gilbert
  • Vinai Gondi (New Investigator Liaison)
  • Matthew Hall
  • Jona Hattangadi-Gluth
  • Fabio Iwamoto
  • Michelle Kim
  • Jonathan Knisely
  • Rupesh Kotecha
  • Andrew Lassman
  • Rimas Lukas
  • Shearwood McClelland III
  • Minesh Mehta 
  • Mark Mishra
  • Yazmin Odia 
  • Joshua Palmer
  • Vinay Puduvalli
  • C. Leland Rogers
  • Scott Soltys
  • Paul Sperduto
  • Jason Tharp
  • Theresa Thomas
  • Daniel Trifiletti
  • Christina Tsien
  • Yoshie Umemura           
  • Michael Vogelbaum
  • Tony J.C. Wang
  • Jeffrey S. Wefel 
  • Jonathan T. Yang

General Committee Members

  • Hani Ashamalla
  • Albert Attia
  • James Battiste
  • Sasha Beyer
  • Nicholas Blondin
  • Deborah Blumenthal
  • Daniela Bota
  • Joseph Bovi
  • Steve Braustein
  • Andrew Brenner
  • Daniel Cahill
  • Arnab Chakravarti 
  • Serah Choi
  • Yunfeng Cui
  • Alexandra N. De Leo 
  • Mahua Dey
  • Aidnag Diaz
  • Bently Doonan
  • James Fink
  • Nichole Fisher
  • John Flickinger
  • Matthew Gallitto 
  • Na Tosha Gatson
  • Mark Gilbert 
  • Jon Glass
  • Vinai Gondi
  • Sharad Goyal
  • Matthew M. Grabowski
  • Sean Grimm
  • Christian Grommes
  • Shalina Gupta-Burt
  • Jona Hattangadi-Gluth
  • Grant Hunter
  • Vikram Jairam
  • Seok-Gu Kang
  • William R. Kennedy
  • Osaama Hassan Khan
  • Deepak Khuntia
  • Connor J. Kinslow
  • Roman Kowalchuk
  • Ryan D. Kraus
  • Timothy Kruser
  • Eric Lehrer
  • Jian Yi Li
  • Robert Liebross
  • Christine Lu-Emerson
  • Sean S. Mahase
  • Rachna Malani
  • Mark Malkin
  • Laurence Masson-Cote
  • Minesh Mehta 
  • Eric A. Mellon
  • Muhammad Altaf Memon
  • Faina Nakhlis
  • Mansoor Nasim
  • Antonio Omuro
  • Shiby Paul
  • Richard Peterson
  • Huong Pham
  • Luke R.G. Pike
  • Paula Rauschkolb
  • Raju Raval
  • Kristin Redmond
  • Charlotte I. Rivers
  • Ian Robins
  • Isabel Arrillaga-Romany
  • David Routman
  • Michael Rutenberg
  • Sean Sachdev
  • Anurag Saraf
  • Christopher Schultz
  • Soma Sengupta
  • Nawal Shaikh
  • Colette J. Shen
  • Wenyin Shi
  • Kevin R. Shiue
  • Hui-Kuo Shu
  • Raj Singh
  • Lindsey Sloan
  • Ashok Srinivasan
  • John Suh
  • Ashley Sumrall
  • Jason Tharp
  • Leonard Tuanquin
  • Scott Turner
  • Kenneth Usuki
  • Michael Vogelbaum 
  • Kyle Wang
  • Zabi Wardak
  • Fangfang Yin
  • Michael Yu
  • Jim Zhong
  • Jay-Jiguang Zhu
  • Andrew H. Zureick

    Study Title Status Phase Disease Category Disease Site
    NRG-BN012A Randomized Phase III Trial Of Pre-Operative Compared To Post-Operative Stereotactic Radiosurgery In Patients With Resectable Brain MetastasesOpen to AccrualIIIBrain [BN]Brain Mets
    NRG-BN011A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter GlioblastomaOpen to AccrualIIIBrain [BN]Malignant Glioma
    NRG-BN010A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Open to AccrualI/IIBrain [BN]Other
    NRG-BN009Phase III Trial of Stereotactic Radiosurgery (SRS) or Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Distant Brain Relapse With Brain Metastasis Velocity ≥4 Brain Metastases/Year

    Open to AccrualIIIBrain [BN]Other
    NRG-BN007A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide In Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated GlioblastomaClosed to AccrualII/IIIBrain [BN]Malignant Glioma
    NRG-BN002Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed GlioblastomaTerminatedIBrain [BN]Malignant Glioma
    RTOG-1122Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or GliosarcomaTerminatedIIBrain [BN]Other
    NRG-BN003Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II MeningiomaOpen to AccrualIIIBrain [BN]Benign Brain Tumors
    NRG-BN005A Phase II Randomized Trial of Proton vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to Intermediate Grade Gliomas.Closed to AccrualIIBrain [BN]Lower Grade Glioma
    RTOG-0627Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma MultiformeTerminatedIIBrain [BN]Other
    RTOG-1114Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System LymphomaTerminatedIIBrain [BN]Other
    RTOG-0834Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma: The CATNON Intergroup TrialClosed to AccrualIIIBrain [BN]Benign Brain Tumors
    RTOG-9110NCCTG 86-72-51: A Phase III Evaluation of Postoperative Radiation in Low Grade Intracranial Astrocytomas and OligodendrogliomasClosed to AccrualIIIBrain [BN]Other
    RTOG-9402Phase III Intergroup Randomized Comparison of Radiation Alone Vs Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic OligodendrogliomasTerminatedIIIBrain [BN]Other
    RTOG-0131A Phase II Trial of Pre-Irradiation and Concurrent Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendrogliomas and Mixed Anaplastic OligoastrocytomasTerminatedIIBrain [BN]CNS Metastatic Disease
    RTOG-9813A Phase III (Phase I Closed) Randomized Study of Radiation Therapy and Temozolomide (IND #60,265) Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma and Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant)TerminatedI/IIIBrain [BN]Other
    RTOG-9802A Phase II Study of Observation in Favorable Low-Grade Glioma and Phase III Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade GliomaTerminatedII/IIIBrain [BN]Other
    RTOG-0837Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients with Newly Diagnosed GlioblastomaTerminatedIIBrain [BN]Other
    RTOG-0424A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High Risk Low-Grade GliomasTerminatedIIBrain [BN]Lower Grade Glioma
    RTOG-0539Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk MeningiomasTerminatedIIBrain [BN]Other
    RTOG-0913Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed GlioblastomaTerminatedI/IIBrain [BN]Other
    RTOG-1205Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent GlioblastomaTerminatedIIBrain [BN]Other

    Stay current with science. Sign up for our newsletter.

    Support NRG Oncology.
    Help Our Cause.

    We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

    Donate Today

    NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.